Kuros Biosciences has the GF Score of 64, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Kuros Biosciences
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Kuros Biosciences (XSWX:KURN) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Kuros Biosciences GF Score Related Terms
XSWX:KURN vs ABT, SYK, MDT: GF Score Comparison
For the Medical Devices subindustry, Kuros Biosciences's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences GF Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's GF Score distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's GF Score falls into.
Kuros Biosciences (XSWX:KURN) has a GF Score of 64 as of Jul. 04, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Kuros Biosciences and its competitors. This is 21% above median its historical median of 53.00. Over the past decade, Kuros Biosciences' GF Score has ranged from 29.00 to 84.00.
Is Kuros Biosciences' GF Score too high?
Kuros Biosciences' current GF Score of 64 is 21% above median its 10-year median of 53.00. Over the past 10 years, this metric has ranged from a low of 29.00 to a high of 84.00. Overall, Kuros Biosciences has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' GF Score compare to ABT and SYK?
Kuros Biosciences' GF Score of 64 can be compared against companies in the Medical Devices & Instruments industry. Historically, Kuros Biosciences' own GF Score has ranged from 29.00 to 84.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Kuros Biosciences and its competitors. Kuros Biosciences's current GF Score is 64, which is 21% above median its own 10-year median of 53.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (XSWX:KURN) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF39.09, compared to a current price of CHF19.12 — trading 51.1% below its estimated fair value. The current GF Score is 64, which is 21% above median its 10-year median of 53.00. Kuros Biosciences' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Kuros Biosciences (XSWX:KURN), the current GF Score is 64 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (XSWX:KURN) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of CHF19.12 is trading 51.1% below its estimated GF Value™ of CHF39.09.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for XSWX:KURN:
GF Score: 64 (21% above median its 10-year median of 53.00)
GF Value™: CHF39.09 vs. price of CHF19.12 (51.1% below fair value)
No single metric tells the full story. See the XSWX:KURN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
64GF Score
Get the complete analysis for XSWX:KURN
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:KURN has been successfully added to your 